Local and systemic immune interactions in malignant gliomas KU Leuven
Glioblastoma (GBM), the most frequent primary intrinsic brain tumor, is without any doubt one of the most devastating diseases known to mankind. GBM are currently being treated with neurosurgical resection followed by radio- and chemotherapy. However, despite this treatment, prognosis for these patients is grim with a median survival of only 15 months and less than 20% 3-year survival rates. Already at diagnosis, GBM cells are infiltrating ...